<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90752">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01948453</url>
  </required_header>
  <id_info>
    <org_study_id>513</org_study_id>
    <nct_id>NCT01948453</nct_id>
  </id_info>
  <brief_title>Effect of Garlic Tablet Some Indicators Related to Atherosclerosis</brief_title>
  <official_title>Effect of Garlic Tablet on Carotid Intima Media Thickness and Flow-mediated Dilation in Patients Undergoing Angioplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University</source>
  <oversight_info>
    <authority>Iran: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether garlic in adjunct to conventional medical
      treatment is  effective in improving carotid intima media thickness (CIMT), Flow mediated
      dilation (FMD) and plasma lipid profile or c-reactive protein of coronary artery disease
      (CAD) patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Carotid Intima Media Thickness</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline and compared to placebo group in Carotid Intima Media Thickness at 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Flow-mediated dilatation</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline and compared to placebo group in Flow-mediated dilatation at 12 weeks</description>
  </secondary_outcome>
  <other_outcome>
    <measure>plasma levels of Alanine Aminotransferase, Aspartate Aminotransferase, creatinine, lipid profile, C-Reactive Protein</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change from baseline in plasma levels at 12 weeks</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Garlic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>daily consumption of two odor controlled garlic tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>daily consumption of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Garlic</intervention_name>
    <description>Garlic tablet in adjunct to medical treatment</description>
    <arm_group_label>Garlic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  angiography confirmed coronary artery disease

          -  lack of consistent use of the garlic in the last month

        Exclusion Criteria:

        Change in type of medication during study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javad Nasrollahzadeh, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Clinical Nutrition and Diet Therapy, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ali Z Mehr, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Department of Cardiology, Rajaei Cardiovascular, Medical &amp; Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marjan M Roshan, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Nutrition and Diet Therapy, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Javad Nasrollahzadeh, PhD</last_name>
    <phone>=98 21 22077424</phone>
    <email>jnasrollahzadeh@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marjan M Roshan, PhD</last_name>
    <email>Marjan_mahdaviroshan@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rajaei Cardiovascular, Medical &amp; Research Center</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 18, 2013</lastchanged_date>
  <firstreceived_date>September 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University</investigator_affiliation>
    <investigator_full_name>Javad Nasrollahzadeh</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>CAD</keyword>
  <keyword>CIMT</keyword>
  <keyword>FMD</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
